United Therapeutics Corporation (UTHR): Price and Financial Metrics
United Therapeutics Corporation (UTHR)
Today's Latest Price: $112.79 USD
Updated Aug 7 6:55pm
Add UTHR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
UTHR Stock Summary
- With a year-over-year growth in debt of -23.81%, UNITED THERAPEUTICS Corp's debt growth rate surpasses merely 12.31% of about US stocks.
- Over the past twelve months, UTHR has reported earnings growth of -519.66%, putting it ahead of just 3.92% of US stocks in our set.
- The volatility of UNITED THERAPEUTICS Corp's share price is greater than that of just 16.23% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be MXL, LSCC, FGEN, SMTC, and ROKU.
- UTHR's SEC filings can be seen here. And to visit UNITED THERAPEUTICS Corp's official web site, go to www.unither.com.
UTHR Stock Price Chart Technical Analysis Charts
UTHR Price/Volume Stats
| Current price | $112.79 | 52-week high | $127.79 |
| Prev. close | $112.20 | 52-week low | $75.58 |
| Day low | $111.64 | Volume | 255,200 |
| Day high | $113.27 | Avg. volume | 586,471 |
| 50-day MA | $117.72 | Dividend yield | N/A |
| 200-day MA | $102.21 | Market Cap | 5.01B |
United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
UTHR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $112.79 | $220.03 | 95% |
We started the process of determining a valid price forecast for UNITED THERAPEUTICS Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 62th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 95.67%. In terms of the factors that were most noteworthy in this DCF analysis for UTHR, they are:
- UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 29.7% of tickers in our DCF set.
- UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 16.23. This coverage rate is greater than that of 84.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 7. This value is greater than merely 22.53% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 91% |
| 1% | 93% |
| 2% | 95% |
| 3% | 97% |
| 4% | 98% |
| 5% | 100% |
Want more companies with a valuation profile/forecast similar to that of UNITED THERAPEUTICS Corp? See NHC, AMPH, HCSG, CBPO, and FMS.
Loading social stream, please wait...